Alagille Syndrome Clinical Trial
Official title:
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome
An open-label, single-arm, multi-centre program providing treatment access to ALGS patients with cholestatic pruritus in the US. Access can be requested through Clinigen Healthcare Ltd via email MirumALGS@clinigengroup.com or telephone +1-877-768-4303.
The objective of this EAP is to provide access to maralixibat for eligible ALGS patients with cholestatic pruritus. Participants will be treated with 400 µg/kg/day with safety and tolerability evaluated on an ongoing basis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04729751 -
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).
|
Phase 2 | |
| Active, not recruiting |
NCT05035030 -
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
|
Phase 3 | |
| Recruiting |
NCT06193928 -
Long-Term Safety and Clinical Outcomes of Livmarli in Patients With Alagille Syndrome (LEAP)
|
||
| Completed |
NCT02160782 -
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)
|
Phase 2 | |
| Completed |
NCT00007033 -
Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease
|
N/A | |
| Suspended |
NCT00571272 -
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
|
||
| Completed |
NCT02057692 -
Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome
|
Phase 2 | |
| Active, not recruiting |
NCT02922751 -
FibroScan™ in Pediatric Cholestatic Liver Disease (FORCE)
|
||
| Completed |
NCT00001642 -
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome
|
N/A | |
| Recruiting |
NCT05488067 -
Atorvastatin Therapy on Xanthoma in Alagille Syndrome
|
Phase 4 | |
| Completed |
NCT04674761 -
Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome
|
Phase 3 | |
| Completed |
NCT02117713 -
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome
|
Phase 2 | |
| Completed |
NCT02131623 -
Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease
|
||
| Completed |
NCT02963077 -
A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
|
Phase 1 | |
| Recruiting |
NCT01793168 -
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
|
||
| Completed |
NCT03082937 -
An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT02047318 -
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)
|
Phase 2 | |
| Completed |
NCT01903460 -
Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome
|
Phase 2 | |
| Completed |
NCT01515631 -
Characterization of Pulmonary Artery Stenoses in Alagille Syndrome - a Medical Record Review
|
||
| Enrolling by invitation |
NCT05846854 -
Decreasing Hemorrhage Risk in Children With Alagille Syndrome
|
N/A |